Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANABNYSE:VCXBNASDAQ:VECTNASDAQ:XNCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$20.22-0.9%$18.97$12.21▼$41.31$594.06M-0.2599,709 shs355,554 shsVCXB10X Capital Venture Acquisition Corp. III$11.07$11.05$10.48▼$12.99$146.01M0.0743,760 shs16,992 shsVECTVectivBio$16.85$16.85$4.25▼$16.98$573.24M0.11N/AN/AXNCRXencor$8.06-1.7%$10.18$7.16▼$27.24$573.49M0.99646,270 shs728,455 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio+4.88%+4.19%+12.71%-3.86%-20.31%VCXB10X Capital Venture Acquisition Corp. III0.00%0.00%0.00%0.00%+1.00%VECTVectivBio0.00%0.00%0.00%0.00%0.00%XNCRXencor+0.74%-6.83%-14.05%-49.72%-61.48%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANABAnaptysBio3.2924 of 5 stars4.43.00.00.02.71.70.6VCXB10X Capital Venture Acquisition Corp. IIIN/AN/AN/AN/AN/AN/AN/AN/AVECTVectivBioN/AN/AN/AN/AN/AN/AN/AN/AXNCRXencor3.4585 of 5 stars3.40.00.03.91.90.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANABAnaptysBio 2.70Moderate Buy$35.8877.42% UpsideVCXB10X Capital Venture Acquisition Corp. III 0.00N/AN/AN/AVECTVectivBio 0.00N/AN/AN/AXNCRXencor 2.89Moderate Buy$29.50266.00% UpsideCurrent Analyst Ratings BreakdownLatest VCXB, VECT, XNCR, and ANAB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025XNCRXencorBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$22.00 ➝ $6.005/6/2025ANABAnaptysBioGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$52.00 ➝ $54.005/1/2025ANABAnaptysBioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$40.00 ➝ $40.004/30/2025XNCRXencorWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$31.004/21/2025XNCRXencorWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform3/26/2025ANABAnaptysBioJohnson RiceSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/5/2025ANABAnaptysBioJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$36.00 ➝ $42.003/4/2025ANABAnaptysBioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$22.00 ➝ $22.003/3/2025ANABAnaptysBioGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy2/28/2025XNCRXencorWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$37.00 ➝ $33.00(Data available from 5/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANABAnaptysBio$111.87M5.31N/AN/A$3.32 per share6.09VCXB10X Capital Venture Acquisition Corp. IIIN/AN/A$0.06 per share176.88($1.49) per shareN/AVECTVectivBio$27.34M20.97N/AN/AN/A∞XNCRXencor$127.23M4.51N/AN/A$10.99 per share0.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANABAnaptysBio-$163.62M-$4.85N/AN/AN/A-289.75%-287.94%-37.25%8/4/2025 (Estimated)VCXB10X Capital Venture Acquisition Corp. III$700KN/A0.00∞N/AN/AN/AN/AN/AVECTVectivBio-$93.74MN/A0.00∞N/AN/AN/AN/AN/AXNCRXencor-$126.09M-$3.06N/AN/AN/A-232.77%-30.92%-21.74%8/4/2025 (Estimated)Latest VCXB, VECT, XNCR, and ANAB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025XNCRXencor-$0.60-$0.66-$0.06-$0.66$23.44 million$32.73 million5/5/2025Q1 2025ANABAnaptysBio-$1.30-$1.28+$0.02-$1.28$15.27 million$27.77 million2/27/2025Q4 2024ANABAnaptysBio-$1.61-$0.72+$0.89-$0.72$10.17 million$43.11 million2/27/2025Q4 2024XNCRXencor-$0.81-$0.62+$0.19-$0.62$17.14 million$52.79 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANABAnaptysBioN/AN/AN/AN/AN/AVCXB10X Capital Venture Acquisition Corp. IIIN/AN/AN/AN/AN/AVECTVectivBioN/AN/AN/AN/AN/AXNCRXencorN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANABAnaptysBioN/A10.2310.23VCXB10X Capital Venture Acquisition Corp. IIIN/AN/AN/AVECTVectivBioN/AN/AN/AXNCRXencor0.016.236.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANABAnaptysBioN/AVCXB10X Capital Venture Acquisition Corp. III13.25%VECTVectivBioN/AXNCRXencorN/AInsider OwnershipCompanyInsider OwnershipANABAnaptysBio33.70%VCXB10X Capital Venture Acquisition Corp. III82.47%VECTVectivBio9.70%XNCRXencor4.76%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANABAnaptysBio10029.38 million20.17 millionOptionableVCXB10X Capital Venture Acquisition Corp. III413.19 million2.31 millionNot OptionableVECTVectivBio3034.02 millionN/ANo DataXNCRXencor28071.15 million66.32 millionOptionableVCXB, VECT, XNCR, and ANAB HeadlinesRecent News About These CompaniesXencor, Inc. (NASDAQ:XNCR) Given Average Recommendation of "Moderate Buy" by BrokeragesMay 16 at 2:58 AM | marketbeat.comJacobs Levy Equity Management Inc. Raises Stock Position in Xencor, Inc. (NASDAQ:XNCR)May 15 at 5:41 AM | marketbeat.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Clover Health Investments (CLOV), Xencor (XNCR) and Intellia Therapeutics (NTLA)May 13 at 9:52 PM | theglobeandmail.comLeerink Partnrs Has Bearish Forecast for Xencor Q2 EarningsMay 13 at 1:13 AM | marketbeat.comWedbush Comments on Xencor's Q2 Earnings (NASDAQ:XNCR)May 13 at 1:13 AM | marketbeat.comResearch Analysts Set Expectations for Xencor Q2 EarningsMay 13 at 1:13 AM | marketbeat.comLeerink Partnrs Estimates Xencor's Q2 Earnings (NASDAQ:XNCR)May 13 at 1:04 AM | americanbankingnews.comWedbush Weighs in on Xencor's Q2 Earnings (NASDAQ:XNCR)May 13 at 1:04 AM | americanbankingnews.comEquities Analysts Offer Predictions for Xencor Q2 EarningsMay 13 at 1:04 AM | americanbankingnews.comWhat is William Blair's Forecast for Xencor Q4 Earnings?May 11, 2025 | americanbankingnews.comXencor (NASDAQ:XNCR) Price Target Lowered to $6.00 at BarclaysMay 10, 2025 | americanbankingnews.comDeep Track Capital LP Has $11.49 Million Stake in Xencor, Inc. (NASDAQ:XNCR)May 9, 2025 | marketbeat.comBraidwell LP Buys 149,083 Shares of Xencor, Inc. (NASDAQ:XNCR)May 8, 2025 | marketbeat.comXencor Reports First Quarter 2025 Financial ResultsMay 7, 2025 | uk.finance.yahoo.comXencor (XNCR) Reports Q1 Loss, Tops Revenue EstimatesMay 7, 2025 | zacks.comXencor (NASDAQ:XNCR) Trading Down 6.1% - Should You Sell?May 7, 2025 | marketbeat.comXencor, Inc. (NASDAQ:XNCR) EVP Nancy Valente Sells 4,616 SharesMay 7, 2025 | insidertrades.comXencor (XNCR) Projected to Post Earnings on ThursdayMay 7, 2025 | americanbankingnews.comDimensional Fund Advisors LP Grows Position in Xencor, Inc. (NASDAQ:XNCR)May 7, 2025 | marketbeat.comBVF Inc. IL Acquires 1,438,760 Shares of Xencor, Inc. (NASDAQ:XNCR)May 6, 2025 | marketbeat.comXencor (XNCR) Expected to Announce Earnings on ThursdayMay 3, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVCXB, VECT, XNCR, and ANAB Company DescriptionsAnaptysBio NASDAQ:ANAB$20.22 -0.18 (-0.88%) Closing price 04:00 PM EasternExtended Trading$20.26 +0.04 (+0.17%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.10X Capital Venture Acquisition Corp. III NYSE:VCXB10X Capital Venture Acquisition Corp. III does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or assets. It intends to identify business opportunities in the field of consumer internet, e-commerce, software, healthcare, transportation/mobility, financial services, artificial intelligence, automation, data science, and Software-as-a-Service. The company was incorporated in 2021 and is based in New York, New York. 10X Capital Venture Acquisition Corp. III operates as a subsidiary of 10X Capital SPAC Sponsor III LLC.VectivBio NASDAQ:VECT$16.85 0.00 (0.00%) As of 05/14/2025VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.Xencor NASDAQ:XNCR$8.06 -0.14 (-1.71%) Closing price 04:00 PM EasternExtended Trading$8.06 0.00 (0.00%) As of 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Retail Investors Are Betting Big on Rocket Lab—Should You Too? Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision Taiwan Semiconductor Stock Is The Gift That Keeps on Giving GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine Alibaba's Earnings Just Changed Everything for the Stock Cisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades An Acquisition Just Made Dick's the Most Exciting Stock in Retail CRSPR Stock Could Be Ready to Deliver on Its Massive Promise Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
